Stevin Zorn, PhD, discusses research into exploitation of a single mechanism of action for possible treatment and prevention of Alzheimer disease, and a possible shift of focus towards experimenting with...
Michael Banks, MD, talks about how 2016 Medicaid criteria has allowed for increased access to direct-acting antiviral therapies among patients with hepatitis C virus for whom the costs of the treatments...
